Not a steroid no boxed warning
Simple once-daily treatmentSimple once-daily treatment

Not an actual patient. Symptoms illustrated.

Before & After

RELIABLE RESULTS ANYWHERE ON
THE BODY

Cream 0.15%  |  Age 6+Cream 0.05%  |  Age 2–5

RELIEF PATIENTS CAN SEE AND FEEL

Review clinical trial photos of patients with atopic dermatitis treated with ZORYVE

Ankle

AnkleAntecubital FossaHandAnkleChestFootUpper LegPopliteal FossaHand and Wrist

RELIEF PATIENTS CAN SEE AND FEEL

Review clinical trial photos of patients with atopic dermatitis treated with ZORYVE

Ankle2

AGE 3, MALE

Actual clinical trial patient

Ankle with atopic dermatitis before treatment - Baseline vIGA-AD = 3

Baseline: vIGA-AD = 3

Actual clinical trial patient

Ankle with atopic dermatitis on Week 1 of treatment - vIGA-AD = 2
Ankle with atopic dermatitis on Week 4 of treatment - vIGA-AD = 1

Antecubital Fossa2

AGE 3, FEMALE

Actual clinical trial patient

Antecubital Fossa with atopic dermatitis before treatment - Baseline vIGA-AD = 3

Baseline: vIGA-AD = 3

Actual clinical trial patient

Antecubital Fossa with atopic dermatitis on Week 1 of treatment - vIGA-AD = 3
Antecubital Fossa with atopic dermatitis on Week 4 of treatment - vIGA-AD = 1

Hand2

AGE 3, FEMALE

Actual clinical trial patient

Hand with atopic dermatitis before treatment - Baseline vIGA-AD = 3

Baseline: vIGA-AD = 3

Actual clinical trial patient

Hand with atopic dermatitis on Week 1 of treatment - vIGA-AD = 2
Hand with atopic dermatitis on Week 4 of treatment - vIGA-AD = 1

Ankle2

AGE 3, MALE

Actual clinical trial patient

Ankle1 with atopic dermatitis before treatment - Baseline vIGA-AD = 3

Baseline: vIGA-AD = 3

Actual clinical trial patient

Ankle1 with atopic dermatitis on Week 1 of treatment - vIGA-AD = 1
Ankle1 with atopic dermatitis on Week 4 of treatment - vIGA-AD = 1

Chest2

AGE 2, MALE

Actual clinical trial patient

Chest with atopic dermatitis before treatment - Baseline vIGA-AD = 3

Baseline: vIGA-AD = 3

Actual clinical trial patient

Chest with atopic dermatitis on Week 1 of treatment - vIGA-AD = 2
Chest with atopic dermatitis on Week 4 of treatment - vIGA-AD = 1

Foot2

AGE 2, FEMALE

Actual clinical trial patient

Foot with atopic dermatitis before treatment - Baseline vIGA-AD = 3

Baseline: vIGA-AD = 3

Actual clinical trial patient

Foot with atopic dermatitis on Week 1 of treatment - vIGA-AD = 1
Foot with atopic dermatitis on Week 4 of treatment - vIGA-AD = 1

Upper Leg2

AGE 2, FEMALE

Actual clinical trial patient

Upper Leg with atopic dermatitis before treatment - Baseline vIGA-AD = 2

Baseline: vIGA-AD = 2

Actual clinical trial patient

Upper Leg with atopic dermatitis on Week 1 of treatment - vIGA-AD = 0
Upper Leg with atopic dermatitis on Week 4 of treatment - vIGA-AD = 0

Popliteal Fossa2

AGE 4, MALE

Actual clinical trial patient

Popliteal Fossa with atopic dermatitis before treatment - Baseline vIGA-AD = 3

Baseline: vIGA-AD = 3

Actual clinical trial patient

Popliteal Fossa with atopic dermatitis on Week 1 of treatment - vIGA-AD = 2
Popliteal Fossa with atopic dermatitis on Week 4 of treatment - vIGA-AD = 1

Hand and Wrist2

AGE 4, FEMALE

Actual clinical trial patient

Hand and Wrist with atopic dermatitis before treatment - Baseline vIGA-AD = 3

Baseline: vIGA-AD = 3

Actual clinical trial patient

Hand and Wrist with atopic dermatitis on Week 1 of treatment - vIGA-AD = 3
Hand and Wrist with atopic dermatitis on Week 4 of treatment - vIGA-AD = 1

vIGA-AD = Validated Investigator Global Assessment-Atopic Dermatitis. vIGA-AD Scale: 4 = Severe, 3 = Moderate, 2 = Mild, 1 = Almost Clear, 0 = Clear

See Efficacy Data

| |

View Safety Profile

| |

Request a Representative